Novo Nordisk to present haemophilia portfolio at upcoming congress

2 hours ago

(AWP Alliance News) - Novo Nordisk AS on Friday said new data will be presented at the upcoming International Society on Thrombosis and Haemostasis Congress relating to its haemophilia portfolio.

The Bagsvaerd, Denmark-based pharmaceuticals company said the presentations are highlighted by multiple analyses of the phase 3 FRONTIER4 study evaluating the long-term efficacy and safety of investigational denecimig across a range of age groups and dosing frequencies.

Additional insights from the portfolio will span clinical and real-world treatment data as well as patient-reported outcomes.

"We are excited to share data across our portfolio, including for denecimig, as each of our studies accounts for that lived reality as we focus on advancing person-centric research that will help bring meaningful impact to the rare blood disorders community," said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk.

Additionally, data from the open-label phase 3 explorer10 study will be presented for the first time, evaluating the efficacy and safety of concizumab in children up to 11 years of age living with haemophilia A or B, with inhibitors.

The use of concizumab in children below 12 years of age with haemophilia A or B, with or without inhibitors, is investigational and not approved by regulatory authorities or available anywhere in the world.

Shares in Novo Nordisk closed up 0.7% at DKK317.95 each in Copenhagen on Friday.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom [at] alliancenews.com